Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 209 articles:
HTML format



Single Articles


    May 2020
  1. HARAKA F, Schumacher SG, Ross A, Mantsoki A, et al
    Effect of history of tuberculosis on specificity of Xpert MTB/RIF.
    Eur Respir J. 2020 May 13. pii: 13993003.00343-2020.
    PubMed    


  2. VAN DEN ELSEN SHJ, Akkerman OW, Wessels M, Jongedijk EM, et al
    Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
    Eur Respir J. 2020 May 12. pii: 13993003.00803-2020.
    PubMed    


  3. DATTA S, Gilman RH, Montoya R, Quevedo Cruz L, et al
    Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.
    Eur Respir J. 2020 May 4. pii: 13993003.00495-2019.
    PubMed     Abstract available


    April 2020
  4. BASU ROY R, Thee S, Blazquez-Gamero D, Falcon-Neyra L, et al
    Performance of immune-based and microbiological tests in children with TB meningitis in Europe - a multi-center Paediatric Tuberculosis Network European Trials Group (ptbnet) study.
    Eur Respir J. 2020 Apr 16. pii: 13993003.02004-2019.
    PubMed     Abstract available


  5. BASHAM CA, Cook VJ, Johnston JC
    Towards a "fourth 90": A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985-2015.
    Eur Respir J. 2020 Apr 7. pii: 13993003.00384-2020.
    PubMed    


  6. SPRUIJT I, Erkens C, van den Hof S, Cobelens F, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  7. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  8. ALAGNA R, Besozzi G, Codecasa LR, Gori A, et al
    Celebrating World Tuberculosis Day at the time of COVID-19.
    Eur Respir J. 2020;55.
    PubMed    


    March 2020
  9. FALZON D, Schunemann HJ, Zignol M, Mirzayev F, et al
    WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence.
    Eur Respir J. 2020;55.
    PubMed    


  10. GUGLIELMETTI L, Huerga H, Khan U, Varaine F, et al
    WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?
    Eur Respir J. 2020;55.
    PubMed    


  11. CEGIELSKI JP, Nahid P, Sotgiu G
    The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  12. GEBRESELASSIE N, Hutubessy R, Vekemans J, den Boon S, et al
    The case for assessing the full value of new tuberculosis vaccines.
    Eur Respir J. 2020;55.
    PubMed    


  13. FIEBIG L, Beyene N, Burny R, Fast CD, et al
    From pests to tests: training rats to diagnose tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  14. HAMADA Y, Figueroa C, Martin-Sanchez M, Falzon D, et al
    The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.
    Eur Respir J. 2020;55.
    PubMed     Abstract available


    February 2020
  15. NIMMO C, Millard J, Brien K, Moodley S, et al
    Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients.
    Eur Respir J. 2020 Feb 14. pii: 13993003.02383-2019.
    PubMed    


    January 2020
  16. RONALD LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, et al
    Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study of Hepatotoxicity, Completion, and Costs.
    Eur Respir J. 2020 Jan 24. pii: 13993003.02048-2019.
    PubMed     Abstract available


  17. FROBERG G, Jansson L, Nyberg K, Obasi B, et al
    Screening and treatment of tuberculosis among pregnant women in Stockholm 2016-2017.
    Eur Respir J. 2020 Jan 16. pii: 13993003.00851-2019.
    PubMed     Abstract available


    December 2019
  18. JONSSON J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J, et al
    Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01886-2019.
    PubMed     Abstract available


  19. DE VRIES G, Commandeur S, Erkens C, Haddad W, et al
    Towards selective tuberculosis screening of people in prison in a low-incidence country.
    Eur Respir J. 2019 Dec 20. pii: 13993003.02209-2019.
    PubMed    


  20. STEK C, Allwood B, Du Bruyn E, Buyze J, et al
    The effect of HIV-associated tuberculosis, tuberculosis-IRIS, and prednisone on lung function.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01692-2019.
    PubMed     Abstract available


  21. RUESEN C, Chaidir L, Ugarte-Gil C, van Ingen J, et al
    Diabetes is associated with genotypically drug-resistant tuberculosis.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01891-2019.
    PubMed    


  22. BOMANJI J, Sharma R, Mittal BR, Gambhir S, et al
    PET/CT features of Extrapulmonary Tuberculosis at first clinical presentation - a cross-sectional observational (18)F-FDG imaging study across six countries.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01959-2019.
    PubMed     Abstract available


  23. GENESTET C, Paret R, Pichat C, Berland JL, et al
    Routine survey of Mycobacterium tuberculosis isolates reveals nosocomial transmission.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01888-2019.
    PubMed    


  24. LEE SW, Kang YA, Jin CE, Kim HC, et al
    Gene-based diagnosis of tuberculosis with a new-generation pathogen enrichment technique.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01885-2019.
    PubMed    


    November 2019
  25. KERKHOFF AD, Sossen B, Schutz C, Reipold EI, et al
    Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV.
    Eur Respir J. 2019 Nov 7. pii: 13993003.01259-2019.
    PubMed    


    October 2019
  26. OLAYANJU O, Esmail A, Limberis J, Dheda K, et al
    A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis.
    Eur Respir J. 2019 Oct 16. pii: 13993003.01181-2019.
    PubMed     Abstract available


  27. BORISOV S, Danila E, Maryandyshev A, Dalcolmo M, et al
    Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
    Eur Respir J. 2019 Oct 10. pii: 13993003.01522-2019.
    PubMed     Abstract available


  28. DIEL R, Schluger NW
    Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
    Eur Respir J. 2019;54.
    PubMed    


  29. CAMINERO JA, Garcia-Basteiro AL, Rendon A, Piubello A, et al
    The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.
    Eur Respir J. 2019;54.
    PubMed    


  30. ZELLWEGER JP
    Screening migrants for tuberculosis and latent TB infection: the reward will come later.
    Eur Respir J. 2019;54.
    PubMed    


    September 2019
  31. AHMAD BB, Kristensen KL, Glenthoj JP, Poulsen A, et al
    Latent tuberculosis infection among minor asylum seekers in Denmark.
    Eur Respir J. 2019 Sep 26. pii: 13993003.01688-2019.
    PubMed    


  32. EL ACHKAR S, Demanche C, Osman M, Rafei R, et al
    Zoonotic tuberculosis in humans assessed by next-generation sequencing: an 18-month nationwide study in Lebanon.
    Eur Respir J. 2019 Sep 26. pii: 13993003.00513-2019.
    PubMed    


  33. SPRUIJT I, Tesfay Haile D, Suurmond J, van den Hof S, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed methods study.
    Eur Respir J. 2019 Sep 19. pii: 13993003.00861-2019.
    PubMed     Abstract available


  34. GAFAR F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Wilffert B, et al
    Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in The Netherlands.
    Eur Respir J. 2019 Sep 12. pii: 13993003.01402-2019.
    PubMed     Abstract available


  35. SOTGIU G, Goletti D, Matteelli A
    Global tuberculosis prevention: should we start from the beginning?
    Eur Respir J. 2019;54.
    PubMed    


  36. REEVE BWP, Centis R, Theron G
    Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals.
    Eur Respir J. 2019;54.
    PubMed    


    August 2019
  37. DIEL R, Kohl TA, Mauer F, Merker M, et al
    Accuracy of whole genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany.
    Eur Respir J. 2019 Aug 29. pii: 13993003.01154-2019.
    PubMed    


  38. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Tuberculosis among asylum-seekers in Milan, Italy: Epidemiological analysis and evaluation of interventions.
    Eur Respir J. 2019 Aug 14. pii: 13993003.00896-2019.
    PubMed     Abstract available


    July 2019
  39. GARCIA-BASTEIRO AL, Hurtado JC, Castillo P, Fernandes F, et al
    Unmasking the hidden tuberculosis mortality burden in a large postmortem study in Maputo Central Hospital, Mozambique.
    Eur Respir J. 2019 Jul 25. pii: 13993003.00312-2019.
    PubMed     Abstract available


    June 2019
  40. GUPTA RK, Rosenberg G, Eriksen J, Lipman M, et al
    Tuberculosis following Renal Transplantation in England, Wales and Northern Ireland: A National Registry-based Cohort Study.
    Eur Respir J. 2019 Jun 27. pii: 13993003.02245-2018.
    PubMed    


  41. COHEN A, Mathiasen VD, Schon T, Wejse C, et al
    The global prevalence of latent tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2019 Jun 20. pii: 13993003.00655-2019.
    PubMed     Abstract available


  42. MELSEW YA, Cheng AC, McBryde ES, Denholm JT, et al
    Profiles of tuberculosis disease activation among contacts of patients with tuberculosis.
    Eur Respir J. 2019 Jun 4. pii: 13993003.00353-2019.
    PubMed    


  43. SNOW KJ, Sawyer SM, Denholm JT, Graham SM, et al
    Explaining variation in the burden of child and adolescent tuberculosis.
    Eur Respir J. 2019;53.
    PubMed    


    May 2019
  44. POORAN A, Davids M, Nel A, Shoko A, et al
    IL-4 subverts mycobacterial containment in M. tuberculosis-infected human macrophages.
    Eur Respir J. 2019 May 16. pii: 13993003.02242-2018.
    PubMed     Abstract available


  45. VASILYEVA I, Mariandyshev A, Kazennyy B, Davidaviciene E, et al
    Early access of bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.
    Eur Respir J. 2019 May 16. pii: 13993003.02208-2018.
    PubMed    


  46. WALKER IF, Shi O, Hicks J, Elsey H, et al
    Analysis of loss to follow up in 4,099 multidrug-resistant pulmonary tuberculosis patients.
    Eur Respir J. 2019 May 9. pii: 13993003.00353-2018.
    PubMed     Abstract available


  47. DEKKERS BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, et al
    Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.
    Eur Respir J. 2019 May 2. pii: 13993003.00373-2019.
    PubMed    


  48. MARTINEZ L, Verma R, Croda J, Horsburgh CR, et al
    Detection, survival and infectious potential of Mycobacterium tuberculosis in the environment: A review of the evidence and epidemiological implications.
    Eur Respir J. 2019 May 2. pii: 13993003.02302-2018.
    PubMed     Abstract available


  49. CHEN YY, Pan SW, Shen HS, Chuang FY, et al
    Declining trend in incidence of tuberculosis in adolescents and young adults in Taiwan.
    Eur Respir J. 2019;53.
    PubMed    


    April 2019
  50. MIGLIORI GB, Nardell E, Yedilbayev A, D'Ambrosio L, et al
    Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.
    Eur Respir J. 2019 Apr 25. pii: 13993003.00391-2019.
    PubMed     Abstract available


  51. FURIN J, Sotgiu G
    Protecting those who serve: are we doing enough to prevent tuberculosis in healthcare workers?
    Eur Respir J. 2019;53.
    PubMed    


    March 2019
  52. LANCIONI C, Swarbrick GM, Park B, Nyendak M, et al
    Recognition of CD8(+) T cell Epitopes to Identify Adults with Pulmonary Tuberculosis.
    Eur Respir J. 2019 Mar 28. pii: 13993003.02053-2018.
    PubMed    


  53. VISCA D, Zampogna E, Sotgiu G, Centis R, et al
    Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.
    Eur Respir J. 2019;53.
    PubMed    


  54. GEBRESELASSIE N, Falzon D, Zignol M, Kasaeva T, et al
    Tuberculosis research questions identified through the WHO policy guideline development process.
    Eur Respir J. 2019;53.
    PubMed    


  55. CHAN PC, Lee PH, Lu MJ, Huang YC, et al
    Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly.
    Eur Respir J. 2019;53.
    PubMed    


    February 2019
  56. APRIANI L, McAllister S, Sharples K, Alisjahbana B, et al
    Latent tuberculosis infection in health care workers in low and middle-income countries: an updated systematic review.
    Eur Respir J. 2019 Feb 20. pii: 13993003.01789-2018.
    PubMed     Abstract available


  57. JOLLIFFE DA, Ganmaa D, Wejse C, Raqib R, et al
    Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.
    Eur Respir J. 2019 Feb 6. pii: 13993003.02003-2018.
    PubMed     Abstract available


    January 2019
  58. PAGE ID, Byanyima R, Hosmane S, Onyachi N, et al
    Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.
    Eur Respir J. 2019 Jan 31. pii: 13993003.01184-2018.
    PubMed     Abstract available


  59. VAN LETH F, Brinkmann F, Cirillo DM, Dheda K, et al
    The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
    Eur Respir J. 2019;53.
    PubMed    


  60. ABUBAKAR I, Lipman M
    Reducing loss to follow-up during treatment for drug-resistant tuberculosis.
    Eur Respir J. 2019;53.
    PubMed    


  61. ROSALES-KLINTZ S, Bruchfeld J, Haas W, Heldal E, et al
    Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.
    Eur Respir J. 2019;53.
    PubMed    


    December 2018
  62. MENZIES D, Trajman A
    New short regimens for latent tuberculosis treatment: safety first!
    Eur Respir J. 2018;52.
    PubMed    


    November 2018
  63. FROBERG G, Jansson L, Bruchfeld J
    Treatment of latent tuberculosis with 12-weeks isoniazid/rifapentine in clinical practice.
    Eur Respir J. 2018 Nov 8. pii: 13993003.01128-2018.
    PubMed    


    October 2018
  64. DALE KD, Trauer JM, Dodd PJ, Houben RMGJ, et al
    Estimating the prevalence of latent tuberculosis in a low incidence setting: Australia.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01218-2018.
    PubMed     Abstract available


  65. NDJEKA N, Schnippel K, Master I, Meintjes G, et al
    High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01528-2018.
    PubMed     Abstract available


  66. GOLETTI D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, et al
    Can we predict tuberculosis cure? Current tools available.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01089-2018.
    PubMed     Abstract available


  67. GAO L, Zhang H, Xin H, Liu J, et al
    Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01470-2018.
    PubMed     Abstract available


  68. COLLIN SM, de Vries G, Lonnroth K, Migliori GB, et al
    Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01449-2018.
    PubMed     Abstract available


  69. LAW S, Daftary A, O'Donnell M, Padayatchi N, et al
    Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01030-2018.
    PubMed     Abstract available


  70. GANDHI NR, Brust JCM, Shah NS
    A new era for treatment of drug-resistant tuberculosis.
    Eur Respir J. 2018;52.
    PubMed    


  71. RUHWALD M, Diel R
    Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis.
    Eur Respir J. 2018;52.
    PubMed    


    September 2018
  72. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, van der Werf MJ, et al
    European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following publication of the new World Health Organization recommendations.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01617-2018.
    PubMed    


  73. CABIBBE AM, Walker TM, Niemann S, Cirillo DM, et al
    Whole Genome Sequencing of Mycobacterium tuberculosis.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01163-2018.
    PubMed     Abstract available


    August 2018
  74. NSENGIYUMVA NP, Mappin-Kasirer B, Oxlade O, Bastos M, et al
    Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
    Eur Respir J. 2018 Aug 30. pii: 13993003.01363-2018.
    PubMed     Abstract available


  75. KIK SV, Schumacher S, Maria Cirillo D, Churchyard G, et al
    An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00946-2018.
    PubMed     Abstract available


  76. AULD SC, Sarita Shah N, Mathema B, Brown TS, et al
    XDR tuberculosis in South Africa: genomic evidence supporting transmission in communities.
    Eur Respir J. 2018 Aug 16. pii: 13993003.00246-2018.
    PubMed     Abstract available


  77. UZORKA JW, Delfos NM, Witte AMC, Scheper H, et al
    Tuberculosis after a borderline QuantiFERON result during screening before infliximab.
    Eur Respir J. 2018;52.
    PubMed    


    June 2018
  78. PONTALI E, Sotgiu G, Tiberi S, Tadolini M, et al
    Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Eur Respir J. 2018 Jun 14. pii: 13993003.00934-2018.
    PubMed    


  79. GUGLIELMETTI L, Tiberi S, Burman M, Kunst H, et al
    QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: A Tuberculosis Network European Trialsgroup (TBnet) study.
    Eur Respir J. 2018 Jun 7. pii: 13993003.00537-2018.
    PubMed    


    May 2018
  80. DOBLER CC, Fox GJ, Douglas P, Viney KA, et al
    Screening for tuberculosis in migrants and visitors from high incidence settings: present and future perspectives.
    Eur Respir J. 2018 May 24. pii: 13993003.00591-2018.
    PubMed     Abstract available


  81. ASSEFA Y, Assefa Y, Woldeyohannes S, Hamada Y, et al
    Three-month daily Rifampicin and Isoniazid compared to six or nine-month Isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Eur Respir J. 2018 May 10. pii: 13993003.00395-2018.
    PubMed    


  82. MOHR E, Hughes J, Reuter A, Trivino Duran L, et al
    Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa.
    Eur Respir J. 2018 May 3. pii: 13993003.00017-2018.
    PubMed     Abstract available


  83. MUSTAZZOLU A, Borroni E, Maria Cirillo D, Giannoni F, et al
    Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009-2016.
    Eur Respir J. 2018 May 3. pii: 13993003.00070-2018.
    PubMed    


  84. ABUBAKAR I, Matteelli A, de Vries G, Zenner D, et al
    Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.
    Eur Respir J. 2018;51.
    PubMed    


  85. VILLANUEVA P, Neth O, Ritz N, Tebruegge M, et al
    Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.
    Eur Respir J. 2018;51.
    PubMed    



  86. "Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey." Dodge R. Lim, Anna S. Dean, Mary Rosary Taguinod-Santiago, Angeli Borbe-Reyes, Andrea Maurizio Cabibbe, Matteo Zignol, Ra
    Eur Respir J. 2018;51.
    PubMed    


    April 2018
  87. OLAYANJU O, Limberis J, Esmail A, Oelofse S, et al
    LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00544-2018.
    PubMed    


  88. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, Centis R, et al
    ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update.
    Eur Respir J. 2018 Apr 20. pii: 13993003.02678-2017.
    PubMed     Abstract available


  89. CABIBBE AM, Trovato A, De Filippo MR, Ghodousi A, et al
    Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00387-2018.
    PubMed    


  90. CHANG KC, Chung-Ching Leung E, Law WS, Leung WM, et al
    Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00159-2018.
    PubMed    


    March 2018
  91. LYLES G, Ogarkov O, Zhdanova S, Peloquin CA, et al
    Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.
    Eur Respir J. 2018 Mar 29. pii: 13993003.00109-2018.
    PubMed    


  92. JAFARI C, Olaru ID, Daduna F, Ernst M, et al
    Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.
    Eur Respir J. 2018 Mar 29. pii: 13993003.02189-2017.
    PubMed     Abstract available


  93. LIM DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, et al
    Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey.
    Eur Respir J. 2018 Mar 1. pii: 13993003.02571-2017.
    PubMed    


  94. KIM CT, Kim TO, Shin HJ, Ko YC, et al
    Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  95. SAUNDERS MJ, Tovar MA, Datta S, Evans BEW, et al
    Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries.
    Eur Respir J. 2018;51.
    PubMed    


  96. RUDGARD WE, das Chagas NS, Gayoso R, Barreto ML, et al
    Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.
    Eur Respir J. 2018;51.
    PubMed    


  97. MUSVOSVI M, Duffy D, Filander E, Africa H, et al
    T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.
    Eur Respir J. 2018;51.
    PubMed    


  98. GILPIN C, Korobitsyn A, Migliori GB, Raviglione MC, et al
    The World Health Organization standards for tuberculosis care and management.
    Eur Respir J. 2018;51.
    PubMed    


  99. DE VRIES G, van den Hof S, Op de Coul E, van Crevel R, et al
    Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.
    Eur Respir J. 2018;51.
    PubMed    


  100. MUNOZ-TORRICO M, Salazar MA, Millan MJM, Martinez Orozco JA, et al
    Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Eur Respir J. 2018;51.
    PubMed    


  101. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


  102. HALLEUX CM, Falzon D, Merle C, Jaramillo E, et al
    The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


    February 2018
  103. SULIS G, Agliati A, Pinsi G, Bozzola G, et al
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting.
    Eur Respir J. 2018 Feb 8. pii: 13993003.02345-2017.
    PubMed    


  104. AKKERMAN OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, et al
    Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    Eur Respir J. 2018 Feb 1. pii: 13993003.02490-2017.
    PubMed    


  105. CHIANG CY, Trebucq A
    Tuberculosis re-treatment after exclusion of rifampicin resistance.
    Eur Respir J. 2018;51.
    PubMed    


  106. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


  107. JOHNSTON JC, van der Kop ML, Smillie K, Ogilvie G, et al
    The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  108. GARCIA-BASTEIRO AL, Schaaf HS, Diel R, Migliori GB, et al
    Adolescents and young adults: a neglected population group for tuberculosis surveillance.
    Eur Respir J. 2018;51.
    PubMed    


  109. ALVAREZ-URIA G, Midde M
    Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
    Eur Respir J. 2018;51.
    PubMed    


  110. SNOW KJ, Sismanidis C, Denholm J, Sawyer SM, et al
    The incidence of tuberculosis among adolescents and young adults: a global estimate.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  111. HEYCKENDORF J, van Leth F, Kalsdorf B, Olaru ID, et al
    Relapse-free cure from multidrug-resistant tuberculosis in Germany.
    Eur Respir J. 2018;51.
    PubMed    


  112. CHIANG CY, Trebucq A, Piubello A, Rieder HL, et al
    Should gatifloxacin be included in the model list of essential medicines?
    Eur Respir J. 2018;51.
    PubMed    


    January 2018
  113. HEYSELL SK, Ahmed S, Rahman MT, Akhanda MW, et al
    Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
    Eur Respir J. 2018 Jan 18. pii: 13993003.01778-2017.
    PubMed    


  114. ACUNA-VILLAORDUNA C, Jones-Lopez EC, Fregona G, Marques-Rodrigues P, et al
    Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  115. NGWATU BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, et al
    The impact of digital health technologies on tuberculosis treatment: a systematic review.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  116. LOUTET MG, Burman M, Jayasekera N, Trathen D, et al
    National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  117. AL YAQUOBI F, Al-Abri S, Al-Abri B, Al-Abaidani I, et al
    Tuberculosis elimination: a dream or a reality? The case of Oman.
    Eur Respir J. 2018;51.
    PubMed    


  118. VAN DEN ELSEN SHJ, Akkerman OW, Huisman JR, Touw DJ, et al
    Lack of penetration of amikacin into saliva of tuberculosis patients.
    Eur Respir J. 2018;51.
    PubMed    


  119. PADRAO E, Oliveira O, Felgueiras O, Gaio AR, et al
    Tuberculosis and tobacco: is there any epidemiological association?
    Eur Respir J. 2018;51.
    PubMed    


    December 2017
  120. CHE Y, Song Q, Yang T, Ping G, et al
    Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use.
    Eur Respir J. 2017;50.
    PubMed    


  121. CABIBBE AM, Sotgiu G, Izco S, Migliori GB, et al
    Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.
    Eur Respir J. 2017;50.
    PubMed    


  122. ABADIE ME, Strich JR, Kim T, Xie YL, et al
    Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  123. MIOTTO P, Tessema B, Tagliani E, Chindelevitch L, et al
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    November 2017
  124. LUZZATI R, Migliori GB, Zignol M, Cirillo DM, et al
    Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.
    Eur Respir J. 2017;50.
    PubMed    


  125. FALZON D, Migliori GB, Jaramillo E, Weyer K, et al
    Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.
    Eur Respir J. 2017;50.
    PubMed    


  126. FURIN J, Lessem E, Cox V
    Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  127. KUKSA L, Barkane L, Hittel N, Gupta R, et al
    Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Eur Respir J. 2017;50.
    PubMed    


  128. VAN DER WERF MJ, Sotgiu G, Dara M
    Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.
    Eur Respir J. 2017;50.
    PubMed    


  129. ARNOLDUSSEN M, Schimmel H, Op de Coul E, van den Hof S, et al
    Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.
    Eur Respir J. 2017;50.
    PubMed    


    October 2017
  130. VAN DE BERG S, Erkens C, van Rest J, van den Hof S, et al
    Evaluation of tuberculosis screening of immigrants in the Netherlands.
    Eur Respir J. 2017;50.
    PubMed    


  131. HELDAL E
    A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  132. CHESOV D, Ciobanu N, Lange C, Heyckendorf J, et al
    High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Eur Respir J. 2017;50.
    PubMed    


  133. KODAMA C, Lange B, Olaru ID, Khan P, et al
    Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed    


  134. FIEBIG L, Hauer B, Andres M, Haas W, et al
    Tuberculosis screening in asylum seekers in Germany, 2015: characteristics of cases and yield.
    Eur Respir J. 2017;50.
    PubMed    


    September 2017
  135. FOURNIER A, Bernard C, Sougakoff W, Quelet S, et al
    Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.
    Eur Respir J. 2017;50.
    PubMed    


    August 2017
  136. CHEE CBE, KhinMar KW, Sng LH, Jureen R, et al
    The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Eur Respir J. 2017;50.
    PubMed    


  137. CAZABON D, Suresh A, Oghor C, Qin ZZ, et al
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
    Eur Respir J. 2017;50.
    PubMed    


  138. LEE MR, Ho CM, Lee CH, Lee MC, et al
    Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.
    Eur Respir J. 2017;50.
    PubMed    


  139. DOBLER CC, Cheung K, Nguyen J, Martin A, et al
    Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    July 2017
  140. CAMINERO JA, Piubello A, Scardigli A, Migliori GB, et al
    Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Eur Respir J. 2017;50.
    PubMed    


  141. AHMAD KHAN F, Pande T, Tessema B, Song R, et al
    Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy.
    Eur Respir J. 2017;50.
    PubMed    


  142. RAVIGLIONE M, Poznyak V
    Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.
    Eur Respir J. 2017;50.
    PubMed    


  143. IMTIAZ S, Shield KD, Roerecke M, Samokhvalov AV, et al
    Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  144. AHMAD KHAN F, Salim MAH, du Cros P, Casas EC, et al
    Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  145. ZENNER D, Loutet MG, Harris R, Wilson S, et al
    Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  146. GUGLIELMETTI L, Varaine F, Huerga H, Bonnet M, et al
    Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
    Eur Respir J. 2017;50.
    PubMed    


  147. ONI T, Berkowitz N, Kubjane M, Goliath R, et al
    Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  148. MULLERPATTAN JB, Nikam C, Sharma U, Rodrigues C, et al
    Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Eur Respir J. 2017;50.
    PubMed    


    June 2017
  149. SOLOVIC I, Abubakar I, Sotgiu G, Dara M, et al
    Standard operating procedures for tuberculosis care.
    Eur Respir J. 2017;49.
    PubMed    


  150. VAN DER WERF MJ, Kodmon C, Catchpole M
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed    


  151. HELDAL E, Van Deun A, Chiang CY, Rieder HL, et al
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed    


  152. VAN DEUN A, Chiang CY
    Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Eur Respir J. 2017;49.
    PubMed    


  153. BOERE TM, Visser DH, van Furth AM, Lips P, et al
    Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    May 2017
  154. OLARU ID, Heyckendorf J, Andres S, Kalsdorf B, et al
    Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  155. GUGLIELMETTI L
    Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
    Eur Respir J. 2017;49.
    PubMed    


  156. MILLER C, Lonnroth K, Sotgiu G, Migliori GB, et al
    The long and winding road of chest radiography for tuberculosis detection.
    Eur Respir J. 2017;49.
    PubMed    


  157. RAHMAN MT, Codlin AJ, Rahman MM, Nahar A, et al
    An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    April 2017
  158. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  159. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed    


  160. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed    


  161. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed    


  162. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  163. DAVIES FORSMAN L, Bruchfeld J, Alffenaar JC
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


    March 2017
  164. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed    


  165. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed    


  166. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  167. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  168. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed    


  169. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed    


  170. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed    


  171. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed    


  172. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  173. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed    


  174. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed    


  175. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  176. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed    


  177. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed    


  178. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    February 2017
  179. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed    


    January 2017
  180. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed    


  181. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed    


  182. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  183. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed    


  184. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed    


  185. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available



  186. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed    


  187. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed    


    December 2016
  188. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed    


  189. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Abstract available


  190. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed    


    November 2016
  191. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Abstract available


  192. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed    


  193. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed    


  194. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed    


  195. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed    


  196. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed    


  197. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Abstract available


  198. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed    


  199. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed    


    October 2016
  200. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Abstract available


  201. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed    


  202. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Abstract available


  203. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed    


  204. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed    


    September 2016
  205. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Abstract available


    April 2016
  206. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Abstract available


    March 2016
  207. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Abstract available


    January 2016
  208. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed    


  209. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: